Announcements Trials
Browse Landscape

Phase

Phase 1 48Phase 2 46Phase 1/2 23Phase 3 8Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Glioblastoma 8Recurrence 3Astrocytoma 3Gliosarcoma 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Pituitary Neoplasms 1Oligodendroglioma 1Non Small Cell Lung Cancer Metastatic 1Melanoma 1Medulloblastoma 1Glioma 1Ependymoma 1Brain Neoplasms 1Advanced Glioblastoma 1

Interventions

Temozolomide 2veliparib 1Radiotherapy 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Gliosarcoma × Temozolomide × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡